As of 1/4/2021, Emgality has the best-in-class^a commercial access for the preventive treatment of migraine^1,2

^aBest-in-class commercial access indicates the subcutaneous CGRP antibody injection on prescription drug plans with pharmacy benefit coverage for the most lives at or equivalent to Preferred, Covered, Specialty, or Generic on all commercial plans for the preventive treatment of migraine. Does not take into consideration any restrictions set forth by individual plans. Data as of 1/2021.

SELECT IMPORTANT SAFETY INFORMATION
Contraindications
Emgality is contraindicated in patients with serious hypersensitivity to galcanezumab-gnlm or to any of the excipients.

For your eligible, commercially insured patients with migraine or episodic cluster headache,

Get your patients started on Emgality: 1 savings card^a for 2 headache conditions³

Patients can get Emgality for as little as $0 for up to 12 months

Help patients save with the Emgality Savings Card^a

^aOffer good until 12/31/2021 for up to 12 months of Emgality. Patients with commercial drug insurance may be able to pay as little as $0 for their first fill of Emgality. For the second and subsequent fills, patients must have coverage for Emgality through their commercial drug insurance plan to continue to pay as little as $0 per fill. Offer subject to a monthly savings of wholesale acquisition cost plus usual and customary pharmacy charges and a separate $4900 maximum annual savings. Participation in the program requires a valid patient HIPAA authorization. Patient is responsible for any applicable taxes, fees, or amounts exceeding monthly or annual caps. This offer is invalid for patients without commercial drug insurance or those whose prescription claims are eligible to be reimbursed, in whole or in part, by any governmental program, including, without limitation, Medicaid, Medicare, Medicare Part D, Medigap, DoD, VA, TRICARE^®/CHAMPUS, or any state patient or pharmaceutical assistance program. Offer void where prohibited by law and subject to change or discontinue without notice. Card activation is required. Subject to additional terms and conditions, which can be found here.

PA=prior authorization.

SELECT IMPORTANT SAFETY INFORMATION
Hypersensitivity Reactions
Hypersensitivity reactions, including dyspnea, urticaria, and rash, have occurred with Emgality in clinical studies and the postmarketing setting. Cases of anaphylaxis and angioedema have also been reported in the postmarketing setting. If a serious or severe hypersensitivity reaction occurs, discontinue administration of Emgality and initiate appropriate therapy. Hypersensitivity reactions can occur days after administration and may be prolonged.

Request your Emgality Loading Dose Kit samples, delivered by your Lilly Sales Representative^a

The Loading Dose Kit (sample) lets you provide patients living with migraine a chance to try out administering the first monthly dose of Emgality (2 injections of 120 mg each), right in your office. After that, patients can inject 1 dose, or injection, on their own each month. Loading Dose Kits (samples) are intended to assess tolerability and efficacy for individual patients in the office.

To request your loading dose kit samples, use the link below to complete and submit your request electronically. Your Rep will deliver your samples directly to your office.

Sample/Sales Representative Request Form

^aSamples are not available for episodic cluster headache.

SELECT IMPORTANT SAFETY INFORMATION
Adverse Reactions
The most common adverse reactions (incidence ≥2% and at least 2% greater than placebo) in Emgality clinical studies were injection site reactions.

These resources are available for your practice

Dosing and Prescribing Comparison by Indication